Printer Friendly

IMMUNOGEN BEGINS PHASE II TRIALS OF ONCOLYSIN S

 CAMBRIDGE, Mass., Sept. 1 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the initiation of Phase II clinical trials of Oncolysin(R) S, the company's second product, in the treatment of small-cell lung cancer.
 "We completed our initial Phase I safety trial of Oncolysin S in relapsed patients earlier this year," notes Carol L. Epstein, M.D., ImmunoGen vice president and chief medical officer. "That trial established that the drug may be administered safely, is well tolerated and is delivered to the tumor. We also saw evidence of efficacy in more than 30 percent of the patients treated in the Phase I trial. These results were very encouraging, especially since current therapies for relapsed small-cell lung cancer rarely produce durable responses and the longm? prognosis for these patients is poor.
 "We are now moving forward to measure the effectiveness of Oncolysin S in extending the period of disease-free survival of patients who are in remission following conventional chemotherapy," Epstein explains. "By administering the drug to patients in remission, as adjunctive therapy, we believe we may reduce significantly the residual tumor cells that remain following conventional therapy and which cause relapse. This Phase II trial, as well as several other Phase II trials which we expect to begin within the next two months, will measure the effectiveness of Oncolysin S in prolonging patients' disease-free survival. We also will test whether treatment with Oncolysin S can benefit patients by turning partial remissions induced with conventional therapy into complete remissions."
 There are over 48,000 new cases of SCLC each year in the United States. While many SCLC patients can be put into an initial remission using conventional chemotherapy, they almost always relapse in a matter of months. Less than 5 percent of patients survive long-term with SCLC.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first-generation products, the Oncolysins, are each comprised of a highly specific monoclonal antibody linked to blocked ricin, a proprietary derivative of the powerful plant toxin, ricin. The company also is developing small- drug immunoconjugates for use as tumor debulking agents.
 -0- 9/1/93
 /CONTACT: Mark Ratner, director of external communications at ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE004 -- 7778 09/01/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 1, 1993
Words:399
Previous Article:DR. PELLER MARION'S 'CRISIS PROOF YOUR CAREER: FINDING JOB SECURITY IN AN INSECURE TIME' (BIRCH LANE PRESS) RELEASED SEPT. 1
Next Article:LABOR DAY TIPS FOR A SAFE WORKPLACE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters